Search

Your search keyword '"Fiala, Ondřej"' showing total 4 results
Start Over Author "Fiala, Ondřej" Journal clinical genitourinary cancer
4 results on '"Fiala, Ondřej"'

1. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study

Author

Monteiro, Fernando Sabino Marques, Fiala, Ondřej, Massari, Francesco, Myint, Zin W., Kopecky, Jindrich, Kucharz, Jakub, Büttner, Thomas, Grande, Enrique, Bourlon, Maria Teresa, Molina-Cerrillo, Javier, Pichler, Renate, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Bamias, Aristotelis, Bhuva, Dipen, Vau, Nuno, Porta, Camillo, Fay, Andre Poisl, and Santoni, Matteo

Published
2024
Full Text
View/download PDF

2. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)

Author

Santoni, Matteo, Massari, Francesco, Myint, Zin W., Iacovelli, Roberto, Pichler, Martin, Basso, Umberto, Kopecky, Jindrich, Kucharz, Jakub, Buti, Sebastiano, Salfi, Alessia, Büttner, Thomas, De Giorgi, Ugo, Kanesvaran, Ravindran, Fiala, Ondřej, Grande, Enrique, Zucali, Paolo Andrea, Fornarini, Giuseppe, Bourlon, Maria T, Scagliarini, Sarah, Molina-Cerrillo, Javier, Aurilio, Gaetano, Matrana, Marc R, Pichler, Renate, Cattrini, Carlo, Büchler, Tomas, Seront, Emmanuel, Calabrò, Fabio, Pinto, Alvaro, Berardi, Rossana, Zgura, Anca, Mammone, Giulia, Ansari, Jawaher, Atzori, Francesco, Chiari, Rita, Zakopoulou, Roubini, Caffo, Orazio, Procopio, Giuseppe, Bassanelli, Maria, Zampiva, Ilaria, Messina, Carlo, Küronya, Zsófia, Mosca, Alessandra, Bhuva, Dipen, Vau, Nuno, Incorvaia, Lorena, Rebuzzi, Sara Elena, Roviello, Giandomenico, Zabalza, Ignacio Ortego, Rizzo, Alessandro, Mollica, Veronica, Catalini, Ilaria, Monteiro, Fernando Sabino M., Montironi, Rodolfo, Battelli, Nicola, Rizzo, Mimma, and Porta, Camillo

Published
2023
Full Text
View/download PDF

3. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer

Author

Buchler, Tomas, Poprach, Alexandr, Bortlicek, Zbynek, Lakomy, Radek, Chloupková, Renata, Vyzula, Rostislav, Zemanova, Milada, Kopeckova, Katerina, Svoboda, Marek, Slaby, Ondrej, Kiss, Igor, Studentova, Hana, Hornova, Jana, Fiala, Ondrej, Kopecky, Jindrich, Finek, Jindrich, Dusek, Ladislav, and Melichar, Bohuslav

Published
2017
Full Text
View/download PDF

4. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.

Author

Marques Monteiro, Fernando Sabino, Fiala, Ondřej, Massari, Francesco, Myint, Zin W., Kopecky, Jindrich, Kucharz, Jakub, Büttner, Thomas, Grande, Enrique, Bourlon, Maria Teresa, Molina-Cerrillo, Javier, Pichler, Renate, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Bamias, Aristotelis, Bhuva, Dipen, Vau, Nuno, Porta, Camillo, Fay, Andre Poisl, and Santoni, Matteo

Subjects
RENAL cell carcinoma, METASTASIS, BIOMARKERS, CANCER immunotherapy, KINASE inhibitors
Abstract

The treatment of metastatic renal cell carcinoma has evolved on last years. Nowadays immune-combinations are the standard treatment in first-line setting. There is no prognostic biomarker for metastatic renal cell carcinoma in the systemic immunotherapy treatment era. Systemic Immune-Inflammation Index is a cheap and readily available prognostic tool to be used in daily clinical practice. Background: Systemic treatment with immune combinations is the gold standard for metastatic renal cell carcinoma (mRCC) worldwide. The systemic immune-inflammation index (SII) is a prognostic marker for several types of malignant neoplasms, including mRCC, in the era of tyrosine kinase inhibitor (TKI) treatment. Data regarding the prognostic value of the SII in patients with mRCC treated with immunotherapy are scarce and controversial. Methods: We retrospectively collected the data of patients with mRCC from 56 centers in 18 countries. SII (Platelet × Neutrophil/Lymphocyte count) was calculated prior to the first systemic treatment and cut-off was defined by a survival receiver operating characteristic (ROC) analysis. The primary objective of our retrospective study was to assess the outcomes of patients treated with first-line immunotherapy. Results: Data from 1034 mRCC patients was collected and included in this analysis. The SII cut-off value was 1265. After a follow-up of 26.7 months, and the overall survival (OS) and progression-free survival (PFS) were 39.8 and 15.7 months, respectively. According to SII (low vs. high), patients with low-SII had longer OS (55.7 vs. 22.2 months, P < .001), better PFS (20.8 vs. 8.5 months, P < .001), and higher overall response rate (52 vs. 37%, P = .033). Conclusion: A high SII is associated with poor oncological outcomes in patients with mRCC. SII could be an easily accessible prognostic indicator for use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results